Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Hepatic insulin signaling regulates VLDL secretion and atherogenesis in mice
Seongah Han, Chien-Ping Liang, Marit Westerterp, Takafumi Senokuchi, Carrie L. Welch, Qizhi Wang, Michihiro Matsumoto, Domenico Accili, Alan R. Tall
Seongah Han, Chien-Ping Liang, Marit Westerterp, Takafumi Senokuchi, Carrie L. Welch, Qizhi Wang, Michihiro Matsumoto, Domenico Accili, Alan R. Tall
View: Text | PDF
Research Article Cardiology

Hepatic insulin signaling regulates VLDL secretion and atherogenesis in mice

  • Text
  • PDF
Abstract

Type 2 diabetes is associated with accelerated atherogenesis, which may result from a combination of factors, including dyslipidemia characterized by increased VLDL secretion, and insulin resistance. To assess the hypothesis that both hepatic and peripheral insulin resistance contribute to atherogenesis, we crossed mice deficient for the LDL receptor (Ldlr–/– mice) with mice that express low levels of IR in the liver and lack IR in peripheral tissues (the L1B6 mouse strain). Unexpectedly, compared with Ldlr–/– controls, L1B6Ldlr–/– mice fed a Western diet showed reduced VLDL and LDL levels, reduced atherosclerosis, decreased hepatic AKT signaling, decreased expression of genes associated with lipogenesis, and diminished VLDL apoB and lipid secretion. Adenovirus-mediated hepatic expression of either constitutively active AKT or dominant negative glycogen synthase kinase (GSK) markedly increased VLDL and LDL levels such that they were similar in both Ldlr–/– and L1B6Ldlr–/– mice. Knocking down expression of hepatic IR by adenovirus-mediated shRNA decreased VLDL triglyceride and apoB secretion in Ldlr–/– mice. Furthermore, knocking down hepatic IR expression in either WT or ob/ob mice reduced VLDL secretion but also resulted in decreased hepatic Ldlr protein. These findings suggest a dual action of hepatic IR on lipoprotein levels, in which the ability to increase VLDL apoB and lipid secretion via AKT/GSK is offset by upregulation of Ldlr.

Authors

Seongah Han, Chien-Ping Liang, Marit Westerterp, Takafumi Senokuchi, Carrie L. Welch, Qizhi Wang, Michihiro Matsumoto, Domenico Accili, Alan R. Tall

×

Figure 10

The effect of hepatic IR knockdown and of constitutively active GSK (S9A) on VLDL and apoB production in ob/ob mice.

Options: View larger image (or click on image) Download as PowerPoint
The effect of hepatic IR knockdown and of constitutively active GSK (S9A...
(A) Western blot analysis in upper panel shows Ldlr and α-tubulin in WT (C57BL/6J) and ob/ob mice. Center panel shows IR, pAKT, Ldlr, and α-tubulin in ob/ob mice after injection with scrambled adenovirus or IR shRNA. Lower panel shows IR, Ldlr, and α-tubulin from WT mouse treated with scrambled or IR shRNA after 4 weeks of WTD feeding. All livers were collected after a 5-hour fast and 10 days after shRNA adenovirus injection. (B) Tg production in ob/ob mice treated with control adenovirus or IR shRNA. Plasma from each mouse at 0- and 120-minute time points was used for ultracentrifugal preparation of the VLDL fraction. VLDL Tg (C) and VLDL apoB (D) secretion were measured. n = 3–4; *P < 0.05; **P < 0.01. (E) Effect of constitutively active GSK (S9A) on Tg production and apoB levels in ob/ob mice. After a 5-hour fast, Triton WR-1339 was injected and plasma was collected at indicated times from ob/ob mice injected with either empty adenovirus or GSK-S9A. Plasma from each mouse at the 120-minute time point was used for Western blot analysis of apoB. n = 3-4, *P < 0.05, 1-tailed Student’s t test. (F) Western blot analysis of Ldlr and α-tubulin in ob/ob mice after injection with empty or constitutively active GSK (S9A) adenovirus. All livers were collected after 2 weeks of WTD feeding, followed by a 5-hour fast.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts